SPG302 aims to fill this gap by targeting glutamatergic synapse loss, a key contributor to all symptom domains. 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback